通过玻璃体内使用特定的抗-VEGF165 Aptamer（帕塔尼单抗钠）治疗脉络膜新生血管性条纹：长期结果。
Management of CNV in angioid streaks by intravitreal use of specific anti-VEGF165 Aptamer (pegaptanib sodium): long-term results.
机构信息
Department of Ophthalmology, Vakıf Gureba Training and Research Hospital, İstanbul, Turkey.
出版信息
Curr Eye Res. 2011 May;36(5):492-5. doi: 10.3109/02713683.2011.560409.
PURPOSE
To investigate the effectiveness of intravitreal pegaptanib sodium injection in patients with choroidal neovascularization (CNV) secondary to angioid streaks.
METHODS
Five eyes of four patients with angioid streaks with CNV underwent uneventful intravitreal injection of pegaptanib sodium (0.3 mg/90 µL). Patients were followed up with Snellen visual acuity testing, optical coherence tomography, and fundus fluorescein angiography.
RESULTS
The median follow-up time was 18 months (range: 15 to 24 months). Visual acuity improved in two eyes, and stabilized in three out of five eyes. At final examination, CNV regressed with resolution of subretinal fluid in all but one patient with bilateral CNV from angioid streaks.
CONCLUSION
Intravitreal pegaptanib sodium for CNV associated with angioid streaks led to inactivation of most of the CNV lesions, stabilizing or improving visual acuity in all eyes.
目的
观察玻璃体内注射抗血管内皮生长因子单克隆抗体（bevacizumab）治疗伴有脉络膜新生血管（CNV）的异常血管性条纹的临床疗效。
方法
对 4 例 5 眼伴有脉络膜新生血管的异常血管性条纹患者进行玻璃体内注射抗血管内皮生长因子单克隆抗体（bevacizumab）治疗。观察患者的视力、眼底荧光血管造影（FFA）及光相干断层扫描（OCT）等。
结果
随访 15 至 24 个月，平均 18 个月。视力提高 2 眼，稳定 3 眼。所有患者的脉络膜新生血管均消退，视网膜下积液均吸收。
结论
玻璃体内注射抗血管内皮生长因子单克隆抗体（bevacizumab）治疗伴有脉络膜新生血管的异常血管性条纹安全有效，能使大部分脉络膜新生血管消退，稳定或提高视力。
Zotero 插件